Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 44% Improvement Relative Risk Mortality (b) 66% Mortality (c) 62% Mortality (d) -60% c19early.org/s Madan et al. Remdesivir for COVID-19 LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? Retrospective 658 patients in India Lower mortality with remdesivir (p=0.035) Madan et al., medRxiv, doi:10.1101/2021.07.15.21260600 Favors remdesivir Favors control
Remdesivir for the treatment of COVID-19 disease: A retrospective comparative study of patients treated with and without Remdesivir
Madan et al., medRxiv, doi:10.1101/2021.07.15.21260600 (Preprint)
Madan et al., Remdesivir for the treatment of COVID-19 disease: A retrospective comparative study of patients treated with.., medRxiv, doi:10.1101/2021.07.15.21260600 (Preprint)
Jul 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 1,262 hospitalized patients, 398 treated with remdesivir, showing unadjusted lower mortality with treatment, and a treatment delay-response relationship.
[Gérard, Zhou] show significantly increased risk of acute kidney injury with remdesivir. This study is excluded in the after exclusion results of meta analysis: excessive unadjusted differences between groups.
risk of death, 44.4% lower, RR 0.56, p = 0.03, treatment 23 of 398 (5.8%), control 27 of 260 (10.4%), NNT 22, unadjusted.
risk of death, 65.6% lower, RR 0.34, p = 0.04, treatment 4 of 112 (3.6%), control 27 of 260 (10.4%), NNT 15, unadjusted, <5 days from onset.
risk of death, 61.7% lower, RR 0.38, p = 0.009, treatment 9 of 226 (4.0%), control 27 of 260 (10.4%), NNT 16, unadjusted, 5-10 days from onset.
risk of death, 60.5% higher, RR 1.60, p = 0.18, treatment 10 of 60 (16.7%), control 27 of 260 (10.4%), unadjusted, >10 days from onset.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Madan et al., 19 Jul 2021, retrospective, India, preprint, 22 authors.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperRemdesivirAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.07.15.21260600; this version posted July 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Title: Remdesivir for the treatment of COVID-19 disease: A retrospective comparative study of patients treated with and without Remdesivir Authors names and affiliations Surabhi Madan Department of Infectious Diseases Care Institute of Medical Sciences Ahmedabad, India Amit Patel Department of Pulmonary Medicine Care Institute of Medical Sciences Ahmedabad, India Kartikae Sharan Department of Clinical Research Care Institute of Medical Sciences Ahmedabad, India Shayon Ghosh Department of Clinical Research Care Institute of Medical Sciences Ahmedabad, India Vishnu Venugopal Department of Clinical Research Care Institute of Medical Sciences Ahmedabad, India Nitesh Shah Department of Pulmonary Medicine Care Institute of Medical Sciences Ahmedabad, India Bhagyesh Shah Department of Critical Care Medicine Care Institute of Medical Sciences Ahmedabad, India Vipul Thakkar Department of Critical Care Medicine Care Institute of Medical Sciences Ahmedabad, India NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.07.15.21260600; this version posted July 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Rashmi Chovatiya Department of Internal Medicine Care Institute of Medical Sciences Ahmedabad, India Hardik Shah Department of Internal Medicine Care Institute of Medical Sciences Ahmedabad, India Pradip Dabhi Department of Pulmonary Medicine Care Institute of Medical Sciences Ahmedabad, India Minesh Patel Department of Critical Care Medicine Care Institute of Medical Sciences Ahmedabad, India Bhowmik Meghnathi Department of Internal Medicine Care Institute of Medical Sciences Ahmedabad, India Vineet Sankhla Department of Cardiology Care Institute of Medical Sciences Ahmedabad, India Vipul Kapoor Department of Cardiology Care Institute of Medical Sciences Ahmedabad, India Tejas Patel Department of Internal Medicine Care Institute of Medical Sciences Ahmedabad, India Maulik Soni Department of Pulmonary Medicine Care Institute of Medical Sciences Ahmedabad, India medRxiv preprint doi: https://doi.org/10.1101/2021.07.15.21260600; this version posted July 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Nirav Bapat Department of Community Medicine GMERS Medical College, Sola Ahmedabad, India Kaivan Shah Department of Clinical Research Care Institute of Medical Sciences Ahmedabad, India Ritanshu Chandarana Department of Clinical Research Care Institute of Medical Sciences Ahmedabad, India Parloop Bhatt Department of Clinical Research Care Institute of Medical Sciences Ahmedabad, India Manish Rana Department of Community Medicine GMERS Medical College, Sola Ahmedabad,..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit